The Republic of Korea provides a 31-month PCT national-phase deadline. Korean translation is required, and nonresident applicants must appoint an agent under the current WIPO national-phase guide.
| Patent office | Ministry of Intellectual Property of the Republic of Korea (MOIP) |
|---|---|
| Entry deadline | 31 months from the priority date. |
| Language / translation | Korean translation is required for the national phase. |
| Representation | The current WIPO guide states that an agent must be appointed if the applicant is not resident in the Republic of Korea. |
| Portfolio question | Korea can be strategically important for semiconductors, electronics, telecom, batteries, automotive, displays, software and advanced manufacturing. |
This page separates current national-phase procedure from strategic filing considerations. Deadlines, fees and office rules can change, so consequential filing decisions should be verified against the official sources listed below.
The current WIPO PCT Applicant's Guide for the Republic of Korea states that national-phase entry is due 31 months from the priority date under both PCT Article 22 and Article 39 routes. This additional month can be useful operationally, but applicants should still work to an earlier internal deadline for translation and agent instructions.
The national phase requires Korean translation of the application material specified in the WIPO guide. For technical specifications, translation should be reviewed for consistent terminology and claim support. Errors can affect prosecution, especially in semiconductor, electronics, software and chemical inventions.
The current WIPO guide states that an agent must be appointed if the applicant is not resident in the Republic of Korea. The guide identifies registered patent attorneys or legal representatives as persons who can act as agent. Applicants should coordinate the power of attorney and local filing instructions before the deadline.
The WIPO guide lists national filing and examination fees and shows that examination charges include a per-claim component. This means claim count can directly affect cost. Applicants should consider whether the international claim set is economically and strategically appropriate before requesting examination.
Korean prosecution applies national law and examination practice. The WIPO guide also describes timing restrictions on certain amendments to international patent applications. Applicants should therefore coordinate translation, examination request and amendment strategy rather than treating these as independent procedural events.
The current WIPO guide states that the Korean office does not permit reinstatement of rights under PCT Rule 49.6. This makes the national-phase deadline particularly important. Applicants should confirm all deadline calculations and avoid relying on restoration as a routine safety mechanism.
Korea can be a high-value jurisdiction for semiconductor fabrication, batteries, displays, consumer electronics, telecom, automotive systems, robotics and software. Manufacturing and competitor concentration can justify filing even when local sales are not the only commercial factor.
The main variables include Korean translation, filing fees, claim-sensitive examination fees, local-agent costs, office-action responses and annual fees after grant. Claim architecture and specification length can therefore influence both legal strategy and budget.
Retain Korea where manufacturing, technology supply chains, competitors, licensing or market value justify the investment. Compare Korea with Japan, China and the United States based on where the invention will be produced, sold, licensed and enforced.
Before entering the national phase in South Korea, re-check the controlling deadline, translation requirements, required application documents, representation rules, official fees and any available restoration or extension mechanism against the current patent-office or WIPO materials linked on this page. A national-phase decision should also confirm that the application being entered is the correct international application and that the claims, description and drawings support the commercial product. Procedural accuracy and portfolio value are separate questions, so both should be reviewed before fees are committed.
Entry into South Korea should be tied to a commercial reason. Relevant evidence can include expected revenue, manufacturing, technically significant infrastructure, competitors, licensees, investors, regulated-market access and the location of acts that could support infringement evidence. A large market is not automatically a high-value patent market for every invention. The strongest decision record states what commercial leverage the right is expected to create and what portfolio cost will be required through prosecution and maintenance.
The PCT application may contain broad claims, but the commercially useful position in South Korea can depend on who performs the claimed steps and how the product is deployed. Server-side, device, system, composition, method or manufacturing claims can create different enforcement positions depending on the technology. Before examination begins, identify the product features that matter, the likely competitor implementation and the evidence that could later show use of the claimed invention.
The national-phase deadline is not only a procedural event. It is a natural point to review product-market fit, licensing discussions, competitor activity, financing, technical changes and prior-art developments. If the invention has changed materially since the priority filing, prosecution strategy should be adjusted within the support available in the original disclosure. Jurisdictions that no longer support a clear business objective can be removed, allowing budget to move toward stronger markets or newer inventions.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Use official filing rules together with market, manufacturing, competitor, licensing, enforcement and technology considerations before committing to long-term prosecution cost.
rd (at) patentbusinesslawyer (dot) com
